KD Logo

TBPH Stock Sees Decline of Approximately -0.24% in Last Five Days

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Theravance Biopharma Inc shares valued at $13,117,335 were purchased by Samaha Eli on May 01 ’24. At $8.75 per share, Samaha Eli acquired 1,499,124 shares. The insider’s holdings grew to 8,511,350 shares worth approximately $71.41 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Also, Farnum Rhonda sold 1,254 shares, netting a total of over 10,922 in proceeds. Following the sale of shares at $8.71 each, the insider now holds 311,733 shares.

Before that, Farnum Rhonda had sold 1,378 shares from its account. In a trade valued at $14,180, the SVP, COMM & MEDICAL AFFAIRS traded Theravance Biopharma Inc shares for $10.29 each. Upon closing the transaction, the insider’s holdings decreased to 1,378 shares, worth approximately $2.78 million.

As published in their initiating research note from BTIG Research on April 12, 2024, Theravance Biopharma Inc [TBPH] has been a Buy and the price target has been revised to $21. Analysts at Evercore ISI downgraded the stock from ‘”an Outperform”‘ to ‘”an In-line”‘ outlook in a report released in early January. As of May 23, 2022, SVB Leerink has initiated its “an Outperform” rating for TBPH. Earlier on November 05, 2021, JP Morgan upgraded its rating. Their new recommendation was “a Neutral” for TBPH stock which previously was a “an Underweight”.

Analyzing TBPH Stock Performance

During the last five days, there has been a drop of approximately -0.24%. Over the course of the year, Theravance Biopharma Inc shares have dropped approximately -25.36%. Shares of the company reached a 52-week high of $11.71 on 01/04/24 and a 52-week low of $8.13 on 05/29/24. A 50-day SMA is recorded $8.88, while a 200-day SMA reached $9.41. Nevertheless, trading volume fell to 0.23 million shares from 0.25 million shares the previous day.

Support And Resistance Levels for Theravance Biopharma Inc (TBPH)

According to the 24-hour chart, there is a support level at 8.29, which, if violated, would cause prices to drop to 8.08. In the upper region, resistance lies at 8.62. The next price resistance is at 8.73. RSI (Relative Strength Index) is 43.01 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.06, which suggests the price will decrease in the coming days. Percent R is at 57.52%, indicating low price movement. Stochastics%K at holding indicates that the stock is to be held.

Most Popular